Psychopharmacology for the Clinician
Open Access
Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
Nicolette Stogios, Margaret K. Hahn, Yona Lunsky, Pushpal Desarkar and Sri Mahavir Agarwal
J Psychiatry Neurosci March 14, 2023 48 (2) E99-E101; DOI: https://doi.org/10.1503/jpn.220200
Nicolette Stogios
From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)
Margaret K. Hahn
From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)
Yona Lunsky
From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)
Pushpal Desarkar
From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)
Sri Mahavir Agarwal
From the Institute of Medical Science, University of Toronto, Toronto, Ont. (Stogios, Hahn, Desarkar, Agarwal); the Schizophrenia Division, Centre for Addiction and Mental Health, Toronto, Ont. (Stogios, Hahn, Agarwal); the Department of Psychiatry, University of Toronto, Toronto, Ont. (Hahn, Lunsky, Desarkar, Agarwal); the Banting and Best Diabetes Centre, University of Toronto, Toronto, Ont. (Hahn, Agarwal); the Azrieli Adult Neurodevelopmental Centre, Centre for Addiction and Mental Health, Toronto, Ont. (Lunsky, Desarkar)
In this issue
Article tools
Metformin for the treatment of antipsychotic-induced metabolic disturbances in people with intellectual and developmental disabilities
Nicolette Stogios, Margaret K. Hahn, Yona Lunsky, Pushpal Desarkar, Sri Mahavir Agarwal
J Psychiatry Neurosci Mar 2023, 48 (2) E99-E101; DOI: 10.1503/jpn.220200
Related Articles
- No related articles found.
Cited By...
- No citing articles found.